Aurobindo Pharma gets NOD for niche drugs, strong pipeline to push earnings.

The approval of anti-bacterial injection, Ertapenem, provides a significant opportunity with limited competition.47908_Aurobindo-Pharma_372

Why this is important?

A complex injectable product launch in the US is good news for aurobindo. This anti-bacterial injection is for treatment of complicated skin and skin infections in adult. This will help the company to overcome the pricing pressure going on in the US.

Stock to be impacted?

This is good news for the company alongwith the FDA clearance of unit IV. (CMP 603, M. Cap 35,447 crs, P/BV 3.02)

Want to Know more?




Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.